- Assistant Professor of Psychiatry and Behavioral Sciences
My research has focused on advancing the use of precision medical approaches for the treatment of opioid use disorder (OUD). The majority of my work has been in human laboratory and clinical settings, and I have leveraged my background in psychology, neuroscience, and behavioral pharmacology to understand (1) relapse risk following treatment induction, (2) medical strategies to better treat OUD, and (3) preventive measures for opioid abuse such as reduction of abuse liability of opioid therapies in persons with chronic and/or acute pain. I have used diverse methodological approaches to better understand the human experience of opioid use and OUD, including neuroimaging, ecological momentary assessments, survey research, and human laboratory studies. My long-term research goal is to produce results that have clinical impact, either by improving treatment outcomes directly or by evaluating and strategizing macro-level changes to improve healthcare for substance use and related disorders.
Huhn AS, Meyer RE, Harris JD, Ayaz H, Izzetoglu K, Deneke E, Bunce SC. Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. Brain Research Bulletin. 2016; 123: 102-109.
Huhn AS, Harris J, Cleveland HH, Lydon D, Stankoski D, Deneke E, Bunce SC. Ecological momentary assessment of mood and craving in patients in treatment for prescription opiate dependence. Brain Research Bulletin. 2016; 123: 94-101.
Huhn AS, Dunn KE. Why aren’t physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment. 2017;
Huhn AS, Tompkins DA, Dunn KE. Treatment accessibility and perceived effectiveness amongst individuals that abuse prescription opioids. Drug and Alcohol Dependence. 2017; 180: 279-285.
Tompkins DA, Huhn AS, Johnson PS, Smith MT, Strain EC, Edwards RR, Johnson MW. "To take or not to take": The association between perceived addiction risk, expected analgesic response, and likelihood of trying novel pain relievers in chronic pain patients. Addiction. 2018; 113(1): 67-79.